{"nctId":"NCT00574249","briefTitle":"Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment","startDateStruct":{"date":"2007-11"},"conditions":["Chronic Plaque Psoriasis"],"count":730,"armGroups":[{"label":"adalimumab + placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: adalimumab","Drug: placebo (vehicle ointment)"]},{"label":"adalimumab + calcipotriol/betamethasone","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: adalimumab","Drug: Calcipotriol/Betamethasone Ointment"]}],"interventions":[{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"name":"Calcipotriol/Betamethasone Ointment","otherNames":["Daivobet"]},{"name":"placebo (vehicle ointment)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is \\>= 18 years of age\n* Subject had a clinical diagnosis of chronic plaque psoriasis for at least 6 months, and has moderate to severe plaque psoriasis\n* Subject must have been treated and failed to respond to, or has a contraindication to, or is intolerant to at least two different systemic therapies, one of which must be cyclosporine, or methotrexate or oral PUVA\n* Subject is judged to be in generally good health as determined by the principal investigator\n\nExclusion Criteria:\n\n* Subject has previous exposure to adalimumab\n* Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy\n* Subject is taking or requires oral or injectible corticosteroids\n* Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced or medication-exacerbated psoriasis or new onset guttate psoriasis\n* Subject considered by the investigator, for any reason, to be an unsuitable candidate\n* Female subject who is pregnant or breast-feeding or considering becoming pregnant\n* Subject has a calcium metabolism disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)","description":"PASI75 is defined as at least a 75% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement being 100%. The outcome measure is the percentage of participants who had at least a 75% PASI score decrease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.9","spread":null},{"groupId":"OG001","value":"64.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a PASI50 Response at Week 16 Compared With Baseline (Week 0)","description":"PASI50 is defined as at least a 50% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 50% PASI score decrease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7","spread":null},{"groupId":"OG001","value":"80.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a PASI90 Response at Week 16 Compared With Baseline (Week 0)","description":"PASI90 is defined as at least a 90% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 90% PASI score decrease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.3","spread":null},{"groupId":"OG001","value":"38.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a PASI100 Response at Week 16 Compared With Baseline (Week 0)","description":"PASI100 is defined as at least a 100% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst) with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 100% PASI score decrease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":null},{"groupId":"OG001","value":"15.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 2","description":"PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 4","description":"PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null},{"groupId":"OG001","value":"33.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16.","description":"PSSI is a physician assessment of clinical symptoms of scalp psoriasis. Computed as the sum of scores for erythema, induration, and desquamation (1 = absent; 4 = severest possible) multiplied by involved area (0 = 0%; 6 = 90-100%). Total score range: 0 (best) to 72 (worst). Negative change and percent change from Baseline indicate improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-100.00","spread":null},{"groupId":"OG001","value":"-100.00","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in Nail Psoriasis Severity Index (NAPSI) at Week 16.","description":"NAPSI is a sum of 2 scores that grade nail matrix psoriasis (based on presence/absence of pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (based on presence/absence of onycholysis splinter hemorrhages, oil drop \\[salmon patch\\] discoloration, and nail bed hyperkeratosis). Each fingernail is given a single score based on presence of psoriasis in quadrant of nail: 0 (none) to 4 (present in 4/4 nail quadrants). Score range: 0 (best) to 80 (worst). Negative change and percent change from Baseline indicate improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.00","spread":null},{"groupId":"OG001","value":"-37.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 8","description":"PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":null},{"groupId":"OG001","value":"42.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 12","description":"PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.8","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Physicians Global Assessment (PGA) Response of Clear or Minimal at Week 16","description":"PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 Compared With Baseline (Week 0)","description":"DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.46","spread":"49.171"},{"groupId":"OG001","value":"-67.20","spread":"45.463"}]}]}]},{"type":"SECONDARY","title":"Percent Change in the Dermatology Life Quality Index (DLQI) Total Score at Week 2 Compared With Baseline (Week 0)","description":"DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.14","spread":"44.118"},{"groupId":"OG001","value":"-47.49","spread":"41.093"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 4 Compared With Baseline (Week 0)","description":"DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.64","spread":"68.139"},{"groupId":"OG001","value":"-60.93","spread":"38.122"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 8 Compared With Baseline (Week 0)","description":"DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.30","spread":"45.404"},{"groupId":"OG001","value":"-62.30","spread":"43.087"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 12 Compared With Baseline (Week 0)","description":"DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.49","spread":"45.030"},{"groupId":"OG001","value":"-66.75","spread":"49.195"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 16 Compared With Baseline (Week 0)","description":"Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 16 is calculated as (Week 16 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.53","spread":"31.603"},{"groupId":"OG001","value":"19.71","spread":"32.136"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 8 Compared With Baseline (Week 0)","description":"Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 8 is calculated as (Week 8 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.35","spread":"30.264"},{"groupId":"OG001","value":"18.22","spread":"29.967"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":364},"commonTop":["Nasopharyngitis","Headache","Psoriasis","Pruritus","Cough"]}}}